Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases

Stanford inventors have developed a mesenchymal stem cell-based gene therapy that can target the inflammatory environment and secrete immunomodulatory cytokines. The model has been demonstrated in bone marrow mesenchymal stem cells in vitro. The inflammation-targeting molecules are expressed in approximately 90% of mesenchymal stem cells at 24 hours post-electroporation. The immunomodulatory cytokines can be detectable for more than 48 hours and convert the pro-inflammatory response into an anti-inflammatory tissue repair/regeneration response.